Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix Inc (OCUL)
:OCUL
RESEARCH TOOLSreports
Holding OCUL?
Track your performance easily
OCUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.76 - $11.78
Previous CloseN/A
Volume219.73K
Average Volume (3M)861.26K
Market Cap
$1.24B
Enterprise Value$1.10B
Total Cash (Recent Filing)$68.14M
Total Debt (Recent Filing)$14.09M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Mar 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding157,217,420
10 Day Avg. Volume907,242
30 Day Avg. Volume861,262
Standard Deviation0.27
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)20.80
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue17.92
Enterprise Value/Gross Profit20.71
Enterprise Value/Ebitda-7.15
Forecast
1Y Price Target
$18.00Price Target Upside123.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Ocular Therapeutix News
PremiumCompany Announcements
Ocular Therapeutix Reports Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe fast enrollment completion for SOL-1 reflects a strong demand for a durable treatment option for wet AMD.
Financial OutlookThere is a strong cash position with $427.2M in cash at the end of September 2024.
Product DevelopmentThe potential to expand Axpaxli to additional retinal indications is seen as a positive development.
Bears Say
Clinical TrialsFailure of OTX-TKI or OTX-TIC in clinical trials poses a significant risk.
Financial RiskPotential dilution risk is a concern for investors.
Revenue PerformanceTotal revenue showed only 2.3% growth and failed to meet the projected $16.8M.
---
Ownership Overview
7.57% Insiders
9.91% Mutual Funds
0.45% Other Institutional Investors
70.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCUL FAQ
What was Ocular Therapeutix Inc’s price range in the past 12 months?
Ocular Therapeutix Inc lowest stock price was $3.76 and its highest was $11.78 in the past 12 months.
What is Ocular Therapeutix Inc’s market cap?
Ocular Therapeutix Inc’s market cap is $1.24B.
When is Ocular Therapeutix Inc’s upcoming earnings report date?
Ocular Therapeutix Inc’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.
How were Ocular Therapeutix Inc’s earnings last quarter?
Ocular Therapeutix Inc released its earnings results on Nov 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.023.
Is Ocular Therapeutix Inc overvalued?
According to Wall Street analysts Ocular Therapeutix Inc’s price is currently Undervalued.
Does Ocular Therapeutix Inc pay dividends?
Ocular Therapeutix Inc does not currently pay dividends.
What is Ocular Therapeutix Inc’s EPS estimate?
Ocular Therapeutix Inc’s EPS estimate is -0.25.
How many shares outstanding does Ocular Therapeutix Inc have?
Ocular Therapeutix Inc has 157,217,420 shares outstanding.
What happened to Ocular Therapeutix Inc’s price movement after its last earnings report?
Ocular Therapeutix Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went down -6.415%.
Which hedge fund is a major shareholder of Ocular Therapeutix Inc?
Currently, no hedge funds are holding shares in OCUL
---
Ocular Therapeutix Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (123.60% Upside)
$18.00 (123.60% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $255.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.66%
12-Months-Change
Fundamentals
Return on Equity
-96.89%
Trailing 12-Months
Asset Growth
201.98%
Trailing 12-Months
Company Description
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
---
OCUL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighting significant progress in clinical trial enrollment, strong demand for AXPAXLI, and a solid financial position. The only notable concern was the need for both SOL-1 and SOL-R data for regulatory submission, which may impact timelines. Overall, the outlook is promising, especially with the continued success of DEXTENZA and the anticipation of strong results from the AXPAXLI trials.Read More>---
OCUL Stock 12 Month Forecast
Average Price Target
$18.00
▲(123.60% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Kala Pharmaceuticals
―
Opus Genetics
―
vTv Therapeutics
―
Clearside Biomedical
―
Celldex
―
Best Analysts Covering OCUL
1 Year
1 Year Success Rate
12/23 ratings generated profit
1 Year Average Return
+30.13%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +30.13% per trade.
---